
|Videos|August 9, 2016
The Role of PARP Inhibitors in Prostate Cancer
Author(s)Christopher E. Barbieri, MD, PhD
Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the role of PARP inhibitors in castration-resistant prostate cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5








































